Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-25T20:18:10.025Z Has data issue: false hasContentIssue false
  • English
  • Français

A primer on binge eating disorder diagnosis and management

Published online by Cambridge University Press:  18 December 2015

Leslie Citrome
Leslie Citrome*
Affiliation:
New York Medical College, Department of Psychiatry and Behavioral Sciences, Valhalla, New York, USA
*
*Address for correspondence: Leslie Citrome, MD, MPH, 11 Medical Park Drive, Suite 106, Pomona, NY 10970, USA.(Email: [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Binge eating disorder (BED) is the most common eating disorder, with an estimated lifetime prevalence of 2.6% among U.S. adults, yet often goes unrecognized. In the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), BED is defined by recurrent episodes of binge eating (eating in a discrete period of time an amount of food larger than most people would eat in a similar amount of time under similar circumstances and a sense of lack of control over eating during the episode), occurring on average at least once a week for 3 months, and associated with marked distress. It can affect both men and women, regardless if they are at normal weight, overweight, or obese, and regardless of their ethnic or racial group. Psychiatric comorbidities are very common, with 79% of adults with BED also experiencing anxiety disorders, mood disorders, impulse control disorders, or substance use disorders; almost 50% of persons with BED have ≥3 psychiatric comorbidities. Multiple neurobiological explanations have been proffered for BED, including dysregulation in reward center and impulse control circuitry, with potentially related disturbances in dopamine neurotransmission and endogenous μ‐opioid signaling. Additionally, there is interplay between genetic influences and environmental stressors. Psychological treatments such as cognitive behavioral interventions have been recommended as first line and are supported by meta-analytic reviews. Unfortunately, routine medication treatments for anxiety and depression do not necessarily ameliorate the symptoms of BED; however, at present, there is one approved agent for the treatment of moderate to severe BED—lisdexamfetamine, a stimulant that was originally approved for the treatment of attention deficit hyperactivity disorder.

Keywords

binge eating disordercognitive-behavioral therapyinter-personal therapylisdexamfetamine
Type
CME Review Article
Information
CNS Spectrums , Volume 20 , Issue S1: CME SUPPLEMENT , December 2015 , pp. 41 - 51
Copyright
© Cambridge University Press 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

This activity is supported by an unrestricted educational grant from Shire Pharmaceuticals Inc.

References

1.Hudson, JI, Hiripi, E, Pope, HG, Kessler, RC. The prevalence and correlates of eating disorder in the National Comorbidity Survey Replication. Biol Psychiatry. 2007; 61(3): 348–358.CrossRefGoogle ScholarPubMed
2.Kessler, RC, Berglund, PA, Chiu, WT, et al. The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys. Biol Psychiatry. 2013; 73(9): 904–914.CrossRefGoogle ScholarPubMed
3.Marques, L, Alegria, M, Becker, AE, et al. Comparative prevalence, correlates of impairment, and service utilization for eating disorders across US ethnic groups: implications for reducing ethnic disparities in health care access for eating disorders. Int J Eat Disord. 2011; 44(5): 412–420.CrossRefGoogle ScholarPubMed
4.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA: American Psychiatric Association; 2013.Google Scholar
5.Wilson, GT. Treatment of binge eating disorder. Psychiatr Clin North Am. 2011; 34(4): 773–783.CrossRefGoogle ScholarPubMed
6.Vocks, S, Tuschen-Caffier, B, Pietrowsky, R, Rustenbach, SJ, Kersting, A, Herpertz, S. Meta-analysis of the effectiveness of psychological and pharmacological treatments for binge eating disorder. Int J Eat Disord. 2010; 43(3): 205–217.CrossRefGoogle ScholarPubMed
7.Citrome, L. Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication—what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2015; 69(4): 410–421.CrossRefGoogle ScholarPubMed
8.Grilo, CM, Crosby, RD, Masheb, RM, et al. Overvaluation of shape and weight in binge eating disorder, bulimia nervosa, and sub-threshold bulimia nervosa. Behav Res Ther. 2009; 47(8): 692–696.CrossRefGoogle ScholarPubMed
9.Herman, BK, Safikhani, S, Hengerer, D, et al. The patient experience with DSM-5-defined binge eating disorder: characteristics, barriers to treatment, and implications for primary care physicians. Postgrad Med. 2014; 126(5): 52–63.CrossRefGoogle ScholarPubMed
10.Hamburger, WW. Emotional aspects of obesity. Med Clin North Am. 1951; 35(2): 483–499.CrossRefGoogle ScholarPubMed
11.Stunkard, AJ. Eating patterns and obesity. Psychiatr Q. 1959; 33: 284–295.CrossRefGoogle ScholarPubMed
12.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed. Washington, DC: American Psychiatric Association; 1980.Google Scholar
13.Yanovski, SZ. Binge eating disorder: current knowledge and future directions. Obes Res. 1993; 1(4): 306–324.Google ScholarPubMed
14.Grace, PS, Jacobson, RS, Fullager, CJ. A pilot comparison of purging and non-purging bulimics. J Clin Psychol. 1985; 41(2): 173–180.3.0.CO;2-N>CrossRefGoogle ScholarPubMed
15.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed., rev. Washington, DC: American Psychiatric Association; 1987.Google Scholar
16.Spitzer, RL, Devlin, MJ, Walsh, BT, et al. Binge eating disorder: to be or not to be in DSM-IV. Int J Eat Disord. 1991; 10(6): 627–629.3.0.CO;2-4>CrossRefGoogle Scholar
17.Spitzer, RL, Devlin, MJ, Walsh, BT, et al. Binge eating disorder: a multisite field trial of the diagnostic criteria. Int J Eat Disord. 1991; 11(3): 191–203.3.0.CO;2-S>CrossRefGoogle Scholar
18.Spitzer, RL, Yanovski, S, Wadden, T, et al. Binge eating disorder: its further validation in a multisite study. Int J Eat Disord. 1993; 13(2): 137–153.3.0.CO;2-#>CrossRefGoogle Scholar
19.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
20.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text rev. Washington, DC: American Psychiatric Association; 2000.Google Scholar
21.Fairburn, CG, Bohn, K. Eating disorder NOS (EDNOS): an example of the troublesome “not otherwise specified” (NOS) category in DSM-IV. Behav Res Ther. 2005; 43(6): 691–701.CrossRefGoogle ScholarPubMed
22.Schienle, A, Schäfer, A, Hermann, A, Vaitl, D. Binge-eating disorder: reward sensitivity and brain activation to images of food. Biol Psychiatry. 2009; 65(8): 654–661.CrossRefGoogle ScholarPubMed
23.Balodis, IM, Molina, ND, Kober, H, et al. Divergent neural substrates of inhibitory control in binge eating disorder relative to other manifestations of obesity. Obesity (Silver Spring). 2013; 21(2): 367–377.CrossRefGoogle ScholarPubMed
24.Schäfer, A, Vaitl, D, Schienle, A. Regional grey matter volume abnormalities in bulimia nervosa and binge-eating disorder. Neuroimage. 2010; 50(2): 639–643.CrossRefGoogle ScholarPubMed
25.Davis, C, Levitan, RD, Yilmaz, Z, Kaplan, AS, Carter, JC, Kennedy, JL. Binge eating disorder and the dopamine D2 receptor: genotypes and sub-phenotypes. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 38(2): 328–335.CrossRefGoogle ScholarPubMed
26.Wang, GJ, Geliebter, A, Volkow, ND, et al. Enhanced striatal dopamine release during food stimulation in binge eating disorder. Obesity (Silver Spring). 2011; 19(8): 1601–1608.CrossRefGoogle ScholarPubMed
27.Nathan, PJ, Bullmore, ET. From taste hedonics to motivational drive: central μ-opioid receptors and binge-eating behaviour. Int J Neuropsychopharmacol. 2009; 12(7): 995–1008.CrossRefGoogle ScholarPubMed
28.Davis, CA, Levitan, RD, Reid, C, et al. Dopamine for “wanting” and opioids for “liking”: a comparison of obese adults with and without binge eating. Obesity (Silver Spring). 2009; 17(6): 1220–1225.Google ScholarPubMed
29.Davis, C. The epidemiology and genetics of binge eating disorder (BED). CNS Spectr. In press. DOI: 10.1017/S1092852915000462.CrossRefGoogle Scholar
30.Trace, SE, Baker, JH, Peñas-Lledó, E, Bulik, CM. The genetics of eating disorders. Annu Rev Clin Psychol. 2013; 9: 589–620.CrossRefGoogle ScholarPubMed
31.Pike, KM, Wilfley, D, Hilbert, A, Fairburn, CG, Dohm, FA, Striegel‐Moore, RH. Antecedent life events of binge-eating disorder. Psychiatry Res. 2006; 142(1): 19–29.CrossRefGoogle ScholarPubMed
32.Halmi, KA. Perplexities of treatment resistance in eating disorders. BMC Psychiatry. 2013; 13: 292.CrossRefGoogle ScholarPubMed
33.Cossrow, N, Russo, LJ, Ming, EE, Witt, EA, Victor, TW, Wadden, TA. Estimating the prevalence of binge eating disorder in a community sample comparing DSM‐IV‐TR and DSM‐5 criteria. Poster presented at American Psychiatric Association 167th Annual Meeting; May 3–7, 2014; New York, NY.Google Scholar
34.Herman, BK, Deal, LS, DiBenedetti, DB, Nelson, L, Fehnel, SE, Brown, M. Development of the binge eating disorder screener. Poster presented at American Psychiatric Association 168th Annual Meeting; May 16–20, 2015; Toronto, ON.Google Scholar
35. Shire. Binge Eating Disorder Screener-7 (BEDS-7). Available at: http://www.vyvansepro.com/documents/Adult-Binge-Eating-Disorder-Patient-Screener.pdf. Accessed August 27, 2015.Google Scholar
36.Wilson, GT, Grilo, CM, Vitousek, KM. Psychological treatment of eating disorders. Am Psychol. 2007; 62(3): 199–216.CrossRefGoogle ScholarPubMed
37.Wilfley, DE, Agras, WS, Telch, CF, et al. Group cognitive-behavioral therapy and group interpersonal psychotherapy for the nonpurging bulimic individual: a controlled comparison. J Consult Clin Psychol. 1993; 61(2): 296–305.CrossRefGoogle ScholarPubMed
38.Wilfley, DE, Welch, RR, Stein, RI, et al. A randomized comparison of group cognitive-behavioral therapy and group interpersonal psychotherapy for the treatment of overweight individuals with binge-eating disorder. Arch Gen Psychiatry. 2002; 59(8): 713–721.CrossRefGoogle ScholarPubMed
39.Reas, DL, Grilo, CM. Pharmacological treatment of binge eating disorder: update review and synthesis. Expert Opin Pharmacother. 2015; 16(10): 1463–1478.CrossRefGoogle ScholarPubMed
40.Reas, DL, Grilo, CM. Current and emerging drug treatments for binge eating disorder. Expert Opin Emerg Drugs. 2014; 19(1): 99–142.CrossRefGoogle ScholarPubMed
41.McElroy, SL, Guerdjikova, AI, Mori, N, O’Melia, AM. Pharmacological management of binge eating disorder: current and emerging treatment options. Ther Clin Risk Manag. 2012; 8: 219–241.CrossRefGoogle ScholarPubMed
42.Reas, DL, Grilo, CM. Review and meta-analysis of pharmacotherapy for binge-eating disorder. Obesity (Silver Spring). 2008; 16(9): 2024–2038.CrossRefGoogle ScholarPubMed
43. Shire. VYVANSE (lisdexamfetamine dimesylate) capsules, for oral use, CII. Prescribing information. Revised April 2015. Available at http://pi.shirecontent.com/PI/PDFs/Vyvanse_USA_ENG.pdf. Last accessed August 27, 2015.Google Scholar
44.McElroy, SL, Hudson, JI, Mitchell, JE, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015; 72(3): 235–246.CrossRefGoogle ScholarPubMed
45.McElroy, S, Hudson, J, Ferreira-Cornwell, MC, Radewonuk, J, Gasior, M. Randomized controlled safety and efficacy trials of lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder. Poster presented at American Psychiatric Association 167th Annual Meeting; May 3–7, 2014; New York, NY.Google Scholar
46.Citrome, L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand. 2008; 117(6): 412–419.CrossRefGoogle ScholarPubMed
47.Citrome, L. Relative vs. absolute measures of benefit and risk: what’s the difference? Acta Psychiatr Scand. 2010; 121(2): 94–102.CrossRefGoogle ScholarPubMed
48.Citrome, L, Ketter, TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013; 67(5): 407–411.CrossRefGoogle ScholarPubMed
49. Shire. Vyvanse (lisdexamfetamine dimesylate) positive top-line results in maintenance of efficacy study in adults with moderate to severe binge eating disorder. Press release. July 22, 2015. Available at: https://www.shire.com/newsroom/2015/july/vyvanse-positive-top-line-results-in-maintenance-of-efficacy-study-in-adults. Last accessed August 27, 2015.Google Scholar
50.Claudino, AM, de Oliveira, IR, Appolinario, JC, et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry. 2007; 68(9): 1324–1332.CrossRefGoogle ScholarPubMed